P140 Program Update

AI SummaryClose X

ImmuPharma PLC has announced positive progress on its P140 auto-immune technology platform, receiving a supportive first Combined Search and Examination Report for its UK patent application filed in September 2025, with plans for a PCT application to seek protection in key commercial territories. The company also completed a new study with positive results supporting the patent application, and a scientific manuscript detailing the P140 technology and its mechanism of action is in preparation for submission to a peer-reviewed journal. ImmuPharma continues to progress discussions with potential partners for P140, aiming to complete a value-enhancing licensing deal in 2026.

Disclaimer*

Companies

Immupharma (IMM)
UK 100

Latest directors dealings